Project Grant R01CA303558
Award Date 5/15/26
Completion Date 4/30/31
Dollars Obligated $642K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a $2.69 million Project Grant on September 24, 2025, under the Cancer Biology Research program (CFDA 93.396) to investigate the mechanisms and impact of neuregulin 3 (NRG3) induction in bone metastasis. The four-year research initiative, extending through August 31, 2029, will employ molecular and genetic approaches to characterize the NRG3 regulome in the bone microenvironment,...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a Project Grant totaling $714,317 under the Cancer Biology Research program (CFDA 93.396) to support fundamental research on prostate cancer progression and therapeutic resistance. The five-year award, effective August 1, 2025 through July 31, 2030, funds research investigating the molecular mechanisms linking epithelial-mesenchymal transition (EMT), mesenchymal-epithelial transition...
- Federal Grant Award Summary The National Cancer Institute awarded Icahn School of Medicine at Mount Sinai a $682,886 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective May 1, 2026, through April 30, 2031. This five-year research initiative focuses on elucidating the role of ATAD2 (AAA-Adenosine Triphosphatase Domain-containing protein 2) in prostate cancer progression and metastasis. The project addresses a critical clinical need by investigating the mechanisms...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $102,984 to The Trustees of Columbia University in the City of New York (Health Sciences Division) on December 25, 2025, under the Cancer Research Manpower program (CFDA 93.398). The award, with an ultimate completion date of June 30, 2028, supports research titled "Spatiotemporal Resolution of Niche and Genomic Co-Evolution in Brain-Metastatic Organotropism." The project aims to...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $169,000 Project Grant under the Cancer Biology Research program (CFDA 93.396) to Icahn School of Medicine at Mount Sinai, effective August 1, 2025, through July 31, 2027. This research grant supports a two-year investigation into epigenetic regulation of melanoma-associated fibroblast plasticity, specifically examining how histone variant dysfunction affects the tumor microenvironment (TME). The principal...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $2.68 million Project Grant under the Cancer Biology Research program (CFDA 93.396) to Icahn School of Medicine at Mount Sinai, with an award date of August 1, 2025, and a completion date of July 31, 2030. This five-year research initiative, led by Principal Investigator James Manfredi, investigates mutant p53 protein's role in tumorigenesis, invasion, and metastasis. The program comprises four integrated...
- Federal Project Grant Award Summary The National Cancer Institute awarded Icahn School of Medicine at Mount Sinai a $628,394 Project Grant under the Cancer Biology Research program (CFDA 93.396) on May 8, 2026, with a completion date of April 30, 2031. The award funds research to develop and validate a novel patient-derived organoid-tumor microenvironment (PDOT) co-culture system for intrahepatic cholangiocarcinoma (ICCA), a highly aggressive liver cancer with limited treatment options. The...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $147,083 Project Grant to Icahn School of Medicine at Mount Sinai under the Cancer Research Manpower program (CFDA 93.398) for the period August 1, 2025 through July 31, 2027. This award supports mentored postdoctoral research training through an NCI Pathway to Independence Award (K99/R00) mechanism, funding a career development project titled "Deconstructing Pathogenic Myelopoiesis in Cancer Immunosuppression and...
- Federal Grant Award Summary The National Cancer Institute awarded Icahn School of Medicine at Mount Sinai a $697,131 Project Grant under the Cancer Biology Research program (CFDA 93.396) on May 1, 2026, with a completion date of April 30, 2031. This five-year research initiative will investigate the myeloid-stromal axis in colorectal cancer (CRC), specifically examining how interactions between macrophages and cancer-associated fibroblasts (CAFs) suppress anti-tumor immunity and promote tumor...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a Project Grant of $682,886 under the Cancer Biology Research program (CFDA 93.396) to investigate the role of ATAD2 (AAA+ ATPase Containing Domain Protein 2) in prostate cancer progression and metastasis. The five-year project, which commenced May 1, 2026 and concludes April 30, 2031, addresses the critical clinical challenge of metastatic prostate cancer, which remains the...